Barchart Research What to Expect from CCCC Earnings CCCC Generated August 12, 2026 Current Price $3.90 EPS Estimate $$-0.21 Consensus Rating Strong Buy Average Move 5.58% C4 Therapeutics: Cemsidomide Data...
Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Presented at European Hematology...
WATERTOWN, Mass., Aug. 10, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...
Barchart Research What to Expect from CCCC Earnings CCCC Generated August 5, 2026 Current Price $3.62 EPS Estimate $$-0.23 Consensus Rating Strong Buy Average Move 5.58% C4 Therapeutics Reports Tomorrow...
At the 100 µg Recommended Phase 2 Dose (RP2D), Cemsidomide Demonstrated a 53% Overall Response Rate, Including Complete Responses and Minimal Residual Disease (MRD) Negative Status Cemsidomide...
WATERTOWN, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation (TPD) science,...
WATERTOWN, Mass., May 18, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science,...
Barchart Research What to Expect from CCCC Earnings CCCC Generated May 12, 2026 Current Price $3.17 EPS Estimate $$-0.21 Consensus Rating Strong Buy Average Move 6.20% C4 Therapeutics Reports Tuesday:...
Progressed Plans to Establish Cemsidomide as a Potentially Foundational Treatment for Multiple Myeloma; Enrollment Ongoing in Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination with Elranatamab ...
Agreement Focused on Developing DACs With Payloads For Two Oncology Targets, With an Option for a Third Target C4T to Develop Degraders With Payload Properties; Roche to Conjugate Payloads to Targeted...